Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility?
(1991) Biomedicine & Pharmacotherapy — Vol. 45, n° 8, p. 359-362 (1991)
Files
11089.pdf
Restricted Access - Adobe PDF
- 1.74 MB
Details
- Authors
- Abstract
- A link between debrisoquine oxidation phenotype and lung cancer susceptibility has been evoked by some authors but not confirmed by others. For this reason, we compared the frequency of debrisoquine poor metabolizer phenotype in 91 Belgian patients with lung cancer to that studied in 167 healthy Belgian subjects. No significant difference was observed in our study. These results do not support the existence of this link.
- Affiliations
Citations
Horsmans, Y., Desager, J.-P., & Harvengt, C. (1991). Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility? Biomedicine & Pharmacotherapy, 45(8), 359-362. https://doi.org/10.1016/0753-3322(91)90066-3 (Original work published 1991)